Retrieve available abstracts of 9 articles: HTML format
Single Articles
April 2025
FERDINANDUS J, Schneider G, Borchmann P PET evaluation in Hodgkin lymphoma: when to change treatment - Authors' reply.
Lancet. 2025;405:1145. PubMed
SHIMAZU Y PET evaluation in Hodgkin lymphoma: when to change treatment.
Lancet. 2025;405:1144-1145. PubMed
March 2025
PEREZ-GARCIA JM, Gebhart G, Rodriguez-Morato J, Llombart-Cussac A, et al Neoadjuvant therapy in HER2-positive breast cancer and interim PET - Authors'
reply.
Lancet. 2025;405:1055-1056. PubMed
HINDIE E, Groheux D Neoadjuvant therapy in HER2-positive breast cancer and interim PET.
Lancet. 2025;405:1054-1055. PubMed
July 2024
EVENS AM Enhancing the treatment landscape: PET-guided BrECADD for advanced-stage,
classical Hodgkin lymphoma.
Lancet. 2024;404:312-313. PubMed
BORCHMANN P, Ferdinandus J, Schneider G, Moccia A, et al Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in
advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre,
parallel, open-label, phase 3 trial.
Lancet. 2024 Jul 3:S0140-6736(24)01315-1. doi: 10.1016/S0140-6736(24)01315. PubMedAbstract available
April 2024
PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al 3-year invasive disease-free survival with chemotherapy de-escalation using an
(18)F-FDG-PET-based, pathological complete response-adapted strategy in
HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2
trial.
Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054. PubMedAbstract available
February 2024
BAYAS A, Menacher M, Lapa C, Tappe D, et al (18)fluorodeoxyglucose PET/CT as possible early diagnostic tool preceding MRI
changes in Borna disease virus 1 encephalitis.
Lancet. 2024;403:665-666. PubMed
December 2023
TSAI CJ, Yang JT, Shaverdian N, Patel J, et al Standard-of-care systemic therapy with or without stereotactic body radiotherapy
in patients with oligoprogressive breast cancer or non-small-cell lung cancer
(Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an
open-label, randomi
Lancet. 2023 Dec 14:S0140-6736(23)01857-3. doi: 10.1016/S0140-6736(23)01857. PubMedAbstract available